Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12288
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBroadley, Simon Aen
dc.contributor.authorBarnett, Michael Hen
dc.contributor.authorBoggild, Mikeen
dc.contributor.authorBrew, Bruce Jen
dc.contributor.authorButzkueven, Helmuten
dc.contributor.authorHeard, Roberten
dc.contributor.authorHodgkinson, Suzanneen
dc.contributor.authorKermode, Allan Gen
dc.contributor.authorLechner-Scott, Jeannetteen
dc.contributor.authorMacdonell, Richard A Len
dc.contributor.authorMarriott, Marken
dc.contributor.authorMason, Deborah Fen
dc.contributor.authorParratt, Johnen
dc.contributor.authorReddel, Stephen Wen
dc.contributor.authorShaw, Cameron Pen
dc.contributor.authorSlee, Marken
dc.contributor.authorSpies, Judithen
dc.contributor.authorTaylor, Bruce Ven
dc.contributor.authorCarroll, William Men
dc.contributor.authorKilpatrick, Trevor Jen
dc.contributor.authorKing, Johnen
dc.contributor.authorMcCombe, Pamela Aen
dc.contributor.authorPollard, John Den
dc.contributor.authorWilloughby, Ernesten
dc.date.accessioned2015-05-16T01:57:02Z
dc.date.available2015-05-16T01:57:02Z
dc.date.issued2014-06-30en
dc.identifier.citationJournal of Clinical Neuroscience 2014; 21(11): 1835-46en
dc.identifier.govdoc24993135en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12288en
dc.description.abstractMultiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of therapies that have an impact on the long term outcome of the disease have emerged over the past 20 years. In this three part series we review the practicalities, benefits and potential hazards of each of the currently available and emerging treatment options for MS. We pay particular attention to ways of abrogating the risks of these therapies and provide advice on the most appropriate indications for using individual therapies. In Part 1 we review the history of the development of MS therapies and its connection with the underlying immunobiology of the disease. The established therapies for MS are reviewed in detail and their current availability and indications in Australia and New Zealand are summarised. We examine the evidence to support their use in the treatment of MS.en
dc.language.isoenen
dc.subject.otherEvidence-based medicineen
dc.subject.otherGuidelineen
dc.subject.otherMultiple sclerosisen
dc.subject.otherReviewen
dc.subject.otherTreatmenten
dc.titleTherapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Clinical Neuroscienceen
dc.identifier.affiliationWestmead Clinical School, University of Sydney, NSW, Australiaen
dc.identifier.affiliationHunter Medical Research Institute, The University of Newcastle, New Lambton, NSW, Australiaen
dc.identifier.affiliationDepartment of Neurology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationMelbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationCentre for Neuromuscular and Neurological Disorders, University of Western Australia, WA, Australiaen
dc.identifier.affiliationUniversity of Queensland Centre for Clinical Research, QLD, Australiaen
dc.identifier.affiliationInstitute of Immunology and Infectious Diseases, Murdoch University, WA, Australiaen
dc.identifier.affiliationDepartment of Neurology, Gold Coast University Hospital, Southport, QLD, Australiaen
dc.identifier.affiliationSouth Western Sydney Clinical School, University of New South Wales, NSW, Australiaen
dc.identifier.affiliationDepartment of Neurology and St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australiaen
dc.identifier.affiliationCentral Clinical School, University of Sydney, NSW, Australiaen
dc.identifier.affiliationSchool of Medicine, Deakin University, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, The Townsville Hospital, Douglas, QLD, Australiaen
dc.identifier.affiliationBrain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australiaen
dc.identifier.affiliationCentre for Neuroscience and Flinders Medical Centre, Flinders University, SA, Australiaen
dc.identifier.affiliationMenzies Research Institute, University of Tasmania, TAS, Australiaen
dc.identifier.affiliationFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationSchool of Medicine, Griffith University, Gold Coast Campus, QLD 4222, Australiaen
dc.identifier.affiliationDepartment of Neurology, Christchurch Hospital, Christchurch, New Zealand.en
dc.identifier.affiliationDepartment of Neurology, Auckland City Hospital, Auckland, New Zealand.en
dc.identifier.doi10.1016/j.jocn.2014.01.016en
dc.description.pages1835-46en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24993135en
dc.type.austinJournal Articleen
local.name.researcherMacdonell, Richard A L
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Nov 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.